PKC Inhibitor Maintains the Kidney Health of Your Type 2 Patients

From the Spring Research Guide

Sacred Heart Medical Center, Spokane, WA

| Apr 1, 2006

For type 2s who suffer from kidney disease, treatment with ruboxistaurin was shown to reduce albuminuria and maintain estimated glomerular filtration rate (eGFR) for more than one year. Ruboxistaurin—a PKC inhibitor manufactured by Eli Lilly and Company—may have added benefit in established therapies for diabetic kidney disease.

Researchers at the Heart Institute and Sacred Heart Medical Center in Spokane, Washington, conducted a randomized double-blind placebo-controlled multicenter study to evaluate the effects of 32 mg per day of ruboxistaurin for one year in 123 people with type 2 diabetes and persistent albuminuria despite therapy with renin-angiotensin system inhibitors.

After one year, urinary albumin-to-creatinine ratio (ACR) decreased 24 percent in participants treated with ruboxistaurin compared to 9 percent in the placebo group. Participants’ eGFR did not decline significantly in the ruboxistaurin group, whereas the placebo group lost significant eGFR over one year.

Diabetes Care, November 2005

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Kidney Care (Nephropathy), Professional Issues, Type 2 Issues

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.